Literature DB >> 33216132

Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy.

Shane D Falcinelli1,2, Kayla W Kilpatrick3, Jenna Read1, Ross Murtagh1, Brigitte Allard1, Simon Ghofrani1, Jennifer Kirchherr1, Katherine S James1, Erin Stuelke1, Caroline Baker1,4, JoAnn D Kuruc1,4, Joseph J Eron4, Michael G Hudgens3, Cynthia L Gay1,4, David M Margolis1,2,4, Nancie M Archin1,4.   

Abstract

BACKGROUND: The replication-competent human immunodeficiency virus (HIV) reservoir is the major barrier to cure. The quantitative viral outgrowth assay (QVOA), the gold-standard method to quantify replication-competent HIV, is resource intensive, which limits its application in large clinical trials. The intact proviral DNA assay (IPDA) requires minimal cell input relative to QVOA and quantifies both defective and intact proviral HIV DNA, the latter potentially serving as a surrogate marker for replication-competent provirus. However, there are limited cross-sectional and longitudinal data on the relationship between IPDA and QVOA measurements.
METHODS: QVOA and IPDA measurements were performed on 156 resting CD4 T-cell (rCD4) samples from 83 antiretroviral therapy-suppressed HIV-positive participants. Longitudinal QVOA and IPDA measurements were performed on rCD4 from 29 of these participants.
RESULTS: Frequencies of intact, defective, and total proviruses were positively associated with frequencies of replication-competent HIV. Longitudinally, decreases in intact proviral frequencies were strikingly similar to that of replication-competent virus in most participants. In contrast, defective proviral DNA frequencies appeared relatively stable over time in most individuals.
CONCLUSIONS: Changes in frequencies of IPDA-derived intact proviral DNA and replication-competent HIV measured by QVOA are similar. IPDA is a promising high-throughput approach to estimate changes in the frequency of the replication-competent reservoir.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; IPDA; QVOA; cure; decay; longitudinal; reservoir

Year:  2021        PMID: 33216132      PMCID: PMC8253129          DOI: 10.1093/infdis/jiaa718

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

2.  Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Authors:  Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 3.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

4.  Fundamentals of Counting Statistics in Digital PCR: I Just Measured Two Target Copies-What Does It Mean?

Authors:  Svilen Tzonev
Journal:  Methods Mol Biol       Date:  2018

5.  Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy.

Authors:  Annukka Ar Antar; Katharine M Jenike; Sunyoung Jang; Danielle N Rigau; Daniel B Reeves; Rebecca Hoh; Melissa R Krone; Jeanne C Keruly; Richard D Moore; Joshua T Schiffer; Bareng As Nonyane; Frederick M Hecht; Steven G Deeks; Janet D Siliciano; Ya-Chi Ho; Robert F Siliciano
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

6.  Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy.

Authors:  Michael J Peluso; Peter Bacchetti; Kristen D Ritter; Subul Beg; Jun Lai; Jeffrey N Martin; Peter W Hunt; Timothy J Henrich; Janet D Siliciano; Robert F Siliciano; Gregory M Laird; Steven G Deeks
Journal:  JCI Insight       Date:  2020-02-27

7.  Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.

Authors:  Rajesh T Gandhi; Joshua C Cyktor; Ronald J Bosch; Hanna Mar; Gregory M Laird; Albine Martin; Ann C Collier; Sharon A Riddler; Bernard J Macatangay; Charles R Rinaldo; Joseph J Eron; Janet D Siliciano; Deborah K McMahon; John W Mellors
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 7.759

Review 8.  Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir.

Authors:  Zheng Wang; Francesco R Simonetti; Robert F Siliciano; Gregory M Laird
Journal:  Retrovirology       Date:  2018-02-13       Impact factor: 4.602

9.  Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir.

Authors:  Christian Gaebler; Julio C C Lorenzi; Thiago Y Oliveira; Lilian Nogueira; Victor Ramos; Ching-Lan Lu; Joy A Pai; Pilar Mendoza; Mila Jankovic; Marina Caskey; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2019-07-26       Impact factor: 14.307

10.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Authors:  N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

View more
  12 in total

1.  Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART.

Authors:  Catherine R Cochrane; Thomas A Angelovich; Michael Roche; Melissa J Churchill; Sarah J Byrnes; Emily Waring; Aleks C Guanizo; Gemma S Trollope; Jingling Zhou; Judith Vue; Lachlan Senior; Emma Wanicek; Janna Jamal Eddine; Matthew J Gartner; Trisha A Jenkins; Paul R Gorry; Bruce J Brew; Sharon R Lewin; Jacob D Estes
Journal:  Ann Neurol       Date:  2022-08-09       Impact factor: 11.274

Review 2.  An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection.

Authors:  Mathias Lichterfeld; Ce Gao; Xu G Yu
Journal:  Trends Immunol       Date:  2022-08       Impact factor: 19.709

3.  CCL5-Secreting Virtual Memory CD8+ T Cells Inversely Associate With Viral Reservoir Size in HIV-1-Infected Individuals on Antiretroviral Therapy.

Authors:  Wei Hu; Yan-Jun Li; Cheng Zhen; You-Yuan Wang; Hui-Huang Huang; Jun Zou; Yan-Qing Zheng; Gui-Chan Huang; Si-Run Meng; Jie-Hua Jin; Jing Li; Ming-Ju Zhou; Yu-Long Fu; Peng Zhang; Xiao-Yu Li; Tao Yang; Xiu-Wen Wang; Xiu-Han Yang; Jin-Wen Song; Xing Fan; Yan-Mei Jiao; Ruo-Nan Xu; Ji-Yuan Zhang; Chun-Bao Zhou; Jin-Hong Yuan; Lei Huang; Ya-Qin Qin; Feng-Yao Wu; Ming Shi; Fu-Sheng Wang; Chao Zhang
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

4.  Associations Between Multiple Measures of HIV-1 Persistence in Persons on Suppressive Antiretroviral Therapy.

Authors:  Ronald J Bosch; Rajesh T Gandhi; Hanna Mar; Joseph J Eron; Joshua C Cyktor; Deborah K McMahon; John W Mellors
Journal:  J Infect Dis       Date:  2022-06-15       Impact factor: 7.759

5.  Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers.

Authors:  Xiaodong Lian; Ce Gao; Xiaoming Sun; Chenyang Jiang; Kevin B Einkauf; Kyra W Seiger; Joshua M Chevalier; Yuko Yuki; Maureen Martin; Rebecca Hoh; Michael J Peluso; Mary Carrington; Ezequiel Ruiz-Mateos; Steven G Deeks; Eric S Rosenberg; Bruce D Walker; Mathias Lichterfeld; Xu G Yu
Journal:  Sci Transl Med       Date:  2021-12-15       Impact factor: 19.319

6.  Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size.

Authors:  Sherazaan D Ismail; Catherine Riou; Sarah B Joseph; Nancie M Archin; David M Margolis; Alan S Perelson; Tyler Cassidy; Melissa-Rose Abrahams; Matthew Moeser; Olivia D Council; Lyle R McKinnon; Farzana Osman; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald Swanstrom; Carolyn Williamson; Nigel J Garrett; Wendy A Burgers
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 20.999

7.  A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir.

Authors:  Claire N Levy; Sean M Hughes; Pavitra Roychoudhury; Daniel B Reeves; Chelsea Amstuz; Haiying Zhu; Meei-Li Huang; Yulun Wei; Marta E Bull; Noah A J Cassidy; Jan McClure; Lisa M Frenkel; Mars Stone; Sonia Bakkour; Elizabeth R Wonderlich; Michael P Busch; Steven G Deeks; Joshua T Schiffer; Robert W Coombs; Dara A Lehman; Keith R Jerome; Florian Hladik
Journal:  Cell Rep Med       Date:  2021-04-12

8.  Intragenic proviral elements support transcription of defective HIV-1 proviruses.

Authors:  Jeffrey Kuniholm; Elise Armstrong; Brandy Bernabe; Carolyn Coote; Anna Berenson; Samantha D Patalano; Alex Olson; Xianbao He; Nina H Lin; Juan I Fuxman Bass; Andrew J Henderson
Journal:  PLoS Pathog       Date:  2021-12-28       Impact factor: 6.823

9.  HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.

Authors:  F Harrison Omondi; Hanwei Sudderuddin; Aniqa Shahid; Natalie N Kinloch; Bradley R Jones; Rachel L Miller; Olivia Tsai; Daniel MacMillan; Alicja Trocha; Mark A Brockman; Chanson J Brumme; Jeffrey B Joy; Richard Liang; Bruce D Walker; Zabrina L Brumme
Journal:  mBio       Date:  2021-11-16       Impact factor: 7.867

10.  Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA.

Authors:  Christian Gaebler; Shane D Falcinelli; Elina Stoffel; Jenna Read; Ross Murtagh; Thiago Y Oliveira; Victor Ramos; Julio C C Lorenzi; Jennifer Kirchherr; Katherine S James; Brigitte Allard; Caroline Baker; JoAnn D Kuruc; Marina Caskey; Nancie M Archin; Robert F Siliciano; David M Margolis; Michel C Nussenzweig
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.